Original Article

Subject Category: Acquired and Multigenic Disease

Molecular Therapy (2008); doi:10.1038/mt.2008.165

Gene-eluting Stents: Adenovirus-mediated Delivery of eNOS to the Blood Vessel Wall Accelerates Re-endothelialization and Inhibits Restenosis

Faisal Sharif1,2, Sean O Hynes1, Ronan Cooney1, Linda Howard1, Jill McMahon1, Kieran Daly2, James Crowley2, Frank Barry1 and Timothy O'Brien1,2,3

  1. 1Regenerative Medicine Institute, National Centre for Biomedical Science Engineering, National University of Ireland, Galway, Ireland
  2. 2Department of Cardiology, University College Hospital Galway, National University of Ireland, Galway, Ireland
  3. 3Department of Medicine, University College Hospital Galway, National University of Ireland, Galway, Ireland

Correspondence: Timothy O'Brien, Department of Medicine, Clinical Sciences Institute, University College Hospital, Galway, Ireland. E-mail: timothy.obrien@nuigalway.ie

Received 11 May 2007; Accepted 2 July 2008; Published online 19 August 2008.

Top

Abstract

Drug-eluting stents for coronary artery disease results in inhibition of smooth muscle cell (SMC) and endothelial cells which may increase the risk of stent thrombosis. In this study, we attempted to enhance re-endothelialization of deployed stents while simultaneously inhibiting intimal hyperplasia by overexpression of endothelial nitric oxide synthase (eNOS) delivery in the vasculature using an adenovirus gene–eluting stent. Re-endothelialization was significantly greater in vessels obtained from normocholesterolemic animals at day 14 (85.34% plusminus 7.38 versus 62.66% plusminus 10.49; P < 0.05) and day 28 (91.1% plusminus 10 versus 63.1% plusminus 22; P < 0.05) and hypercholesterolemic animals (96.97% plusminus 3.2 versus 28.33% plusminus 38.76; P < 0.05) at day 28 with AdeNOS-eluting stents. At day 28, there was a significant increase in the lumen size [AdeNOS 2.73 mm2 plusminus 1.18, AdbetaGal 0.98 mm2 plusminus 0.98, phosphorylcholine (PC) 1.87 mm2 plusminus 1.18; P < 0.05], and a significant reduction in neointimal formation (AdeNOS 2.32 mm2 plusminus 1.13, AdbetaGal 3.73 mm2 plusminus 0.95, PC 3.2 mm2 plusminus 0.94; P < 0.05), and percent restenosis (AdeNOS 45.23 plusminus 20.81, AdbetaGal 79.6 plusminus 20.31, PC 70.16 plusminus 22.2; P < 0.05) in AdeNOS-stented vessels in comparison with controls from hypercholesterolemic animals, assessed by morphometry and quantitative coronary angiography (AdeNOS 15.95% plusminus 7.63, AdbetaGal 56.9% plusminus 38.6, PC 58 plusminus 34.6; P < 0.05). Stent-based delivery of AdeNOS results in enhanced endothelial regeneration and reduction in neointimal formation as compared with controls. This seems to be a promising treatment strategy for preventing in-stent restenosis (ISR) while simultaneously reducing the risk of stent thrombosis.

Extra navigation

.

naturejobs

ADVERTISEMENT